Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$11.5MCash on Hand
31.4mo Cash Runway
Follow PRFX by emailGet an email when PRFX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PRFX, unsubscribe in one click. Privacy
📣 What PRFX Says Is Next
year-end 2026 · “We had approximately US$11.0 million in cash and short-term deposits as of September 30, 2026, based on preliminary unaudited information, and our majority-owned subsidiary LayerBio expects to begin enrolling patients in the Phase 2 trial of OcuRing™-K before year-end 2026.”
Company press release, Nov 12, 2026 · SEC filing
year-end · “LayerBio, PRF’s majority-owned subsidiary, expects to begin enrolling patients in its U.S. multi-center Phase 2 clinical trial of OcuRing™-K before year-end.”
Company press release, Nov 3, 2026 · SEC filing
year-end · “LayerBio expects to start patient enrollment in the planned U.S. multi-center trial before year-end, following completion of trial start-up activities.”
Company press release, Oct 23, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Shareholder vote PRF Technologies will hold its annual general meeting on December 21, 2026 in Tel Aviv. Shareholders will vote on re-electing director Asaf Shavit, a 5-to-1 reverse split, a 12,000,000-share increase in authorized capital, and retroactive engagement of interim CEO Efi Cohen-Arazi. Form 6-K · SEC filing · Press release
Nov 12, 2026 ·
Listing Nasdaq notified PRF Technologies its shares closed below US$1.00 for 30 consecutive business days and issued a delisting determination, which the company has appealed to a Hearings Panel. The hearing request stays suspension, and shares continue trading on the Nasdaq Capital Market. Form 6-K · SEC filing · Press release
Nov 5, 2026 ·
Legal S.H.N. Financial Investments Ltd. petitioned the Tel Aviv District Court on November 2, 2026 to order a special general meeting to remove three non-external directors and elect three S.H.N. nominees, and seeks interim restrictions on certain company actions. Form 6-K · SEC filing
Nov 3, 2026 ·
Deal PRF Technologies signed a non-binding term sheet with Dotz Nano to license and sell its GridFeed AI energy platform for US$1.0 million, with PRF taking a US$250,000 equity stake in Dotz. Definitive agreements are still being negotiated. Form 6-K · SEC filing · Press release
Oct 23, 2026 ·
Earnings PRF reported preliminary, unaudited cash of about $11.0 million and liabilities of about $2.5 million as of September 30, 2026, with a nine-month operating loss of about $3.7 million. LayerBio expects to begin enrolling patients in the Phase 2 trial of OcuRing-K before year-end. Form 6-K · SEC filing · Press release
Sep 28, 2026 ·
Shareholder vote A shareholder group, S.H.N. Financial Investments Ltd., which says it holds about 5.7% of voting rights, requested a special general meeting to remove the company's directors other than the external directors and appoint three S.H.N. nominees. The company is reviewing the letter and considering next steps. Form 6-K · SEC filing
Sep 16, 2026 ·
PRF Technologies announced GridFeed, its AI energy optimization platform, is exploring the AI and hyperscale data center market, citing IEA projections that data center electricity use will roughly double from 485 TWh in 2025 to 950 TWh in 2030. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Restructuring PRF Technologies plans to establish GridFeed, with its DeepSolar operations, as a standalone wholly owned subsidiary to pursue strategic investment, partnerships and commercial deals. GridFeed will be showcased at Energy Trading Week Europe on September 24–25, 2026. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
PRFX holds $11.5M in cash and short-term investments and burns about $1.1M/quarter from operations,
an estimated runway of 31.4 months at that rate (BioRadar estimate, not company guidance).
Share count 830,613 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PRFX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRFX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.